01875.HK

Aug 23, 2026, 10:24 UTC

TOT Biopharm reported an interim net loss of RMB 58.52 million for the six months ended June 30, 2026, compared with a net profit of RMB 4.06 million a year earlier, with revenue down 49.7% year-on-year to RMB 246 million.